tetano
Editor, Senior Moderator
BMJ
. 2023 Feb 8;380:e074035.
doi: 10.1136/bmj-2022-074035.
Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study
Sarah C J Jorgensen[SUP] 1 [/SUP], Alejandro Hernandez[SUP] 2 [/SUP], Deshayne B Fell[SUP] 2 3 [/SUP], Peter C Austin[SUP] 2 4 [/SUP], Rohan D'Souza[SUP] 5 6 [/SUP], Astrid Guttmann[SUP] 2 4 7 8 [/SUP], Kevin A Brown[SUP] 2 9 10 [/SUP], Sarah A Buchan[SUP] 2 9 11 [/SUP], Jonathan B Gubbay[SUP] 10 12 [/SUP], Sharifa Nasreen[SUP] 2 9 [/SUP], Kevin L Schwartz[SUP] 2 9 10 [/SUP], Mina Tadrous[SUP] 2 13 14 [/SUP], Kumanan Wilson[SUP] 15 16 17 [/SUP], Jeffrey C Kwong[SUP] 18 9 11 19 20 [/SUP]; Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators
Affiliations
Abstract
Objective: To estimate the effectiveness of maternal mRNA covid-19 vaccination during pregnancy against delta and omicron severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and hospital admission in infants.
Design: Test negative design study.
Setting: Community and hospital testing in Ontario, Canada.
Participants: Infants younger than six months of age, born between 7 May 2021 and 31 March 2022, who were tested for SARS-CoV-2 between 7 May 2021 and 5 September 2022.
Intervention: Maternal mRNA covid-19 vaccination during pregnancy.
Main outcome measures: Laboratory confirmed delta or omicron infection or hospital admission of the infant. Multivariable logistic regression estimated vaccine effectiveness, with adjustments for clinical and sociodemographic characteristics associated with vaccination and infection.
Results: 8809 infants met eligibility criteria, including 99 delta cases (4365 controls) and 1501 omicron cases (4847 controls). Infant vaccine effectiveness from two maternal doses was 95% (95% confidence interval 88% to 98%) against delta infection and 97% (73% to 100%) against infant hospital admission due to delta and 45% (37% to 53%) against omicron infection and 53% (39% to 64%) against hospital admission due to omicron. Vaccine effectiveness for three doses was 73% (61% to 80%) against omicron infection and 80% (64% to 89%) against hospital admission due to omicron. Vaccine effectiveness for two doses against infant omicron infection was highest with the second dose in the third trimester (53% (42% to 62%)) compared with the first (47% (31% to 59%)) or second (37% (24% to 47%)) trimesters. Vaccine effectiveness for two doses against infant omicron infection decreased from 57% (44% to 66%) between birth and eight weeks to 40% (21% to 54%) after 16 weeks of age.
Conclusions: Maternal covid-19 vaccination with a second dose during pregnancy was highly effective against delta and moderately effective against omicron infection and hospital admission in infants during the first six months of life. A third vaccine dose bolstered protection against omicron. Effectiveness for two doses was highest with maternal vaccination in the third trimester, and effectiveness decreased in infants beyond eight weeks of age.
. 2023 Feb 8;380:e074035.
doi: 10.1136/bmj-2022-074035.
Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study
Sarah C J Jorgensen[SUP] 1 [/SUP], Alejandro Hernandez[SUP] 2 [/SUP], Deshayne B Fell[SUP] 2 3 [/SUP], Peter C Austin[SUP] 2 4 [/SUP], Rohan D'Souza[SUP] 5 6 [/SUP], Astrid Guttmann[SUP] 2 4 7 8 [/SUP], Kevin A Brown[SUP] 2 9 10 [/SUP], Sarah A Buchan[SUP] 2 9 11 [/SUP], Jonathan B Gubbay[SUP] 10 12 [/SUP], Sharifa Nasreen[SUP] 2 9 [/SUP], Kevin L Schwartz[SUP] 2 9 10 [/SUP], Mina Tadrous[SUP] 2 13 14 [/SUP], Kumanan Wilson[SUP] 15 16 17 [/SUP], Jeffrey C Kwong[SUP] 18 9 11 19 20 [/SUP]; Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators
Affiliations
- PMID: 36754426
- DOI: 10.1136/bmj-2022-074035
Abstract
Objective: To estimate the effectiveness of maternal mRNA covid-19 vaccination during pregnancy against delta and omicron severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and hospital admission in infants.
Design: Test negative design study.
Setting: Community and hospital testing in Ontario, Canada.
Participants: Infants younger than six months of age, born between 7 May 2021 and 31 March 2022, who were tested for SARS-CoV-2 between 7 May 2021 and 5 September 2022.
Intervention: Maternal mRNA covid-19 vaccination during pregnancy.
Main outcome measures: Laboratory confirmed delta or omicron infection or hospital admission of the infant. Multivariable logistic regression estimated vaccine effectiveness, with adjustments for clinical and sociodemographic characteristics associated with vaccination and infection.
Results: 8809 infants met eligibility criteria, including 99 delta cases (4365 controls) and 1501 omicron cases (4847 controls). Infant vaccine effectiveness from two maternal doses was 95% (95% confidence interval 88% to 98%) against delta infection and 97% (73% to 100%) against infant hospital admission due to delta and 45% (37% to 53%) against omicron infection and 53% (39% to 64%) against hospital admission due to omicron. Vaccine effectiveness for three doses was 73% (61% to 80%) against omicron infection and 80% (64% to 89%) against hospital admission due to omicron. Vaccine effectiveness for two doses against infant omicron infection was highest with the second dose in the third trimester (53% (42% to 62%)) compared with the first (47% (31% to 59%)) or second (37% (24% to 47%)) trimesters. Vaccine effectiveness for two doses against infant omicron infection decreased from 57% (44% to 66%) between birth and eight weeks to 40% (21% to 54%) after 16 weeks of age.
Conclusions: Maternal covid-19 vaccination with a second dose during pregnancy was highly effective against delta and moderately effective against omicron infection and hospital admission in infants during the first six months of life. A third vaccine dose bolstered protection against omicron. Effectiveness for two doses was highest with maternal vaccination in the third trimester, and effectiveness decreased in infants beyond eight weeks of age.